# Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)

> **NCT00309881** · PHASE2 · COMPLETED · sponsor: **German CLL Study Group** · enrollment: 75 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **BIOLOGICAL:** rituximab
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** prednisone
- **DRUG:** vincristine sulfate

## Key facts

- **NCT ID:** NCT00309881
- **Lead sponsor:** German CLL Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** 2006-03
- **Final completion:** 2011-03
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2016-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00309881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00309881, "Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00309881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*